Monoclonal Antibody Therapies Beyond Complement for NMOSD and MOGAD

Vyanka Redenbaugh, Eoin P. Flanagan

Research output: Contribution to journalReview articlepeer-review

Abstract

Aquaporin-4 (AQP4)-IgG seropositive neuromyelitis optica spectrum disorders (AQP4-IgG seropositive NMOSD) and myelin oligodendrocyte glycoprotein (MOG)–IgG-associated disease (MOGAD) are inflammatory demyelinating disorders distinct from each other and from multiple sclerosis (MS).While anti-CD20 treatments can be used to treat MS and AQP4-IgG seropositive NMOSD, some MS medications are ineffective or could exacerbate AQP4-IgG seropositive NMOSD including beta-interferons, natalizumab, and fingolimod. AQP4-IgG seropositive NMOSD has a relapsing course in most cases, and preventative maintenance treatments should be started after the initial attack. Rituximab, eculizumab, inebilizumab, and satralizumab all have class 1 evidence for use in AQP4-IgG seropositive NMOSD, and the latter three have been approved by the US Food and Drug Administration (FDA). MOGAD is much more likely to be monophasic than AQP4-IgG seropositive NMOSD, and preventative therapy is usually reserved for those who have had a disease relapse. There is a lack of any class 1 evidence for MOGAD preventative treatment. Observational benefit has been suggested from oral immunosuppressants, intravenous immunoglobulin (IVIg), rituximab, and tocilizumab. Randomized placebo-controlled trials are urgently needed in this area.

Original languageEnglish (US)
JournalNeurotherapeutics
DOIs
StateAccepted/In press - 2022

Keywords

  • Inebilizumab
  • Myelin oligodendrocyte glycoprotein
  • Neuromyelitis optica
  • Rituximab
  • Satralizumab

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Neurology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Monoclonal Antibody Therapies Beyond Complement for NMOSD and MOGAD'. Together they form a unique fingerprint.

Cite this